Skip to main content
Equibles
STOK logo

STOK · Stoke Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track STOK — free

Use STOK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STOK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$26.61 +1.79 (+7.21%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$1.60B
Shares
64.53M
Volume · Oct 20 2.46M Avg daily vol (3M) 903.62K

Stoke Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Stoke Therapeutics, Inc. (STOK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-08-12
Stoke Therapeutics, Inc. (STOK) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-03
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Confident tone Phase III EMPER study progress and enrollment ADOA / STK-002 pipeline advancement SYNGAP1 and early-stage pipeline
Revenue
$9.32M
▼ 32.5% YoY
Diluted EPS
$-0.93
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Stoke Therapeutics, Inc. (STOK) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
Stoke Therapeutics, Inc. (STOK) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Confident tone Four-year Phase 1/2 OLE data update Primary endpoint and label strategy Payer access and commercial readiness
Revenue
$6.23M
▼ 96.1% YoY
Diluted EPS
$-0.79
▼ 141.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-01-12
Stoke Therapeutics, Inc. (STOK) Q4 2025 Earnings Call
Revenue
$1.40M*
▼ 93.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Stoke Therapeutics, Inc. (STOK) Q3 2025 Earnings Call
Revenue
$10.63M
▲ 117.2% YoY
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Stoke Therapeutics, Inc. (STOK) Q2 2025 Earnings Call
Revenue
$13.82M
▲ 186% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-05
Stoke Therapeutics, Inc. (STOK) Q3 2024 Earnings Call
Revenue
$4.89M
▲ 47.9% YoY
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q3
2022-11-14
Stoke Therapeutics, Inc. (STOK) Q3 2022 Earnings Call
Revenue
$2.90M
Diluted EPS
$-0.66
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–10 of 10 webcasts
Key facts CIK 1623526 CUSIP 86150R107 13F (30d) 10 filings 10 filers Visit website Investor relations